Tags

Type your tag names separated by a space and hit enter

Lithium but not carbamazepine augments antidepressant efficacy of mirtazapine in unipolar depression: an open-label study.
World J Biol Psychiatry. 2009; 10(4 Pt 2):390-9.WJ

Abstract

BACKGROUND

The purpose of the present open-label study was to investigate the antidepressant efficacy of lithium and carbamazepine as augmentation strategies in unipolar depressed inpatients.

METHOD

Forty-six patients suffering from unipolar depression (major depressive episode according to DSM-IV criteria) were pre-treated with mirtazapine for 2 weeks initially (week -2 to week 0). Thereafter, the patients received either continuation of mirtazapine monotherapy (n = 23), combination treatment with mirtazapine and lithium (n = 13), or combination therapy with mirtazapine and carbamazepine (n = 10) for further 3 weeks (week 0 to week 3). Severity of depression was estimated weekly using the 21-item version of the Hamilton Depression Rating Scale (21-HAMD). Response was defined by a reduction of at least 50% in the 21-HAMD sum score after 3 weeks of pharmacotherapy (week 0-3).

RESULTS

Additional administration of lithium, but not adjunctive carbamazepine significantly augmented the antidepressant efficacy of mirtazapine in the unipolar depressed patients. Moreover, carbamazepine but not lithium significantly lowered the serum concentrations of mirtazapine.

CONCLUSION

Whereas the clinical importance of anticonvulsants in the treatment of bipolar disorder is not in doubt, the therapeutic efficacy of antiepileptic drugs such as carbamazepine is obviously limited in the pharmacotherapy of unipolar depression.

Authors+Show Affiliations

Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Germany. Cornelius.Schuele@med.uni-muenchen.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article

Language

eng

PubMed ID

18609420

Citation

Schüle, Cornelius, et al. "Lithium but Not Carbamazepine Augments Antidepressant Efficacy of Mirtazapine in Unipolar Depression: an Open-label Study." The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry, vol. 10, no. 4 Pt 2, 2009, pp. 390-9.
Schüle C, Baghai TC, Eser D, et al. Lithium but not carbamazepine augments antidepressant efficacy of mirtazapine in unipolar depression: an open-label study. World J Biol Psychiatry. 2009;10(4 Pt 2):390-9.
Schüle, C., Baghai, T. C., Eser, D., Nothdurfter, C., & Rupprecht, R. (2009). Lithium but not carbamazepine augments antidepressant efficacy of mirtazapine in unipolar depression: an open-label study. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry, 10(4 Pt 2), 390-9. https://doi.org/10.1080/15622970701849978
Schüle C, et al. Lithium but Not Carbamazepine Augments Antidepressant Efficacy of Mirtazapine in Unipolar Depression: an Open-label Study. World J Biol Psychiatry. 2009;10(4 Pt 2):390-9. PubMed PMID: 18609420.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lithium but not carbamazepine augments antidepressant efficacy of mirtazapine in unipolar depression: an open-label study. AU - Schüle,Cornelius, AU - Baghai,Thomas C, AU - Eser,Daniela, AU - Nothdurfter,Caroline, AU - Rupprecht,Rainer, PY - 2008/7/9/pubmed PY - 2010/3/2/medline PY - 2008/7/9/entrez SP - 390 EP - 9 JF - The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry JO - World J. Biol. Psychiatry VL - 10 IS - 4 Pt 2 N2 - BACKGROUND: The purpose of the present open-label study was to investigate the antidepressant efficacy of lithium and carbamazepine as augmentation strategies in unipolar depressed inpatients. METHOD: Forty-six patients suffering from unipolar depression (major depressive episode according to DSM-IV criteria) were pre-treated with mirtazapine for 2 weeks initially (week -2 to week 0). Thereafter, the patients received either continuation of mirtazapine monotherapy (n = 23), combination treatment with mirtazapine and lithium (n = 13), or combination therapy with mirtazapine and carbamazepine (n = 10) for further 3 weeks (week 0 to week 3). Severity of depression was estimated weekly using the 21-item version of the Hamilton Depression Rating Scale (21-HAMD). Response was defined by a reduction of at least 50% in the 21-HAMD sum score after 3 weeks of pharmacotherapy (week 0-3). RESULTS: Additional administration of lithium, but not adjunctive carbamazepine significantly augmented the antidepressant efficacy of mirtazapine in the unipolar depressed patients. Moreover, carbamazepine but not lithium significantly lowered the serum concentrations of mirtazapine. CONCLUSION: Whereas the clinical importance of anticonvulsants in the treatment of bipolar disorder is not in doubt, the therapeutic efficacy of antiepileptic drugs such as carbamazepine is obviously limited in the pharmacotherapy of unipolar depression. SN - 1814-1412 UR - https://www.unboundmedicine.com/medline/citation/18609420/Lithium_but_not_carbamazepine_augments_antidepressant_efficacy_of_mirtazapine_in_unipolar_depression:_an_open_label_study_ L2 - http://www.tandfonline.com/doi/full/10.1080/15622970701849978 DB - PRIME DP - Unbound Medicine ER -